December 2025

Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.

B.Pharm or D.Pharm from a recognized University. Must have registered with Tamil Nadu Pharmacy Council and must keep the registration alive by renewing it regularly every year.

Doctor of Philosophy in any area of Life Sciences or Biotechnology or Chemical or Computational and Information or Agricultural or Pharmaceutical or Veterinary Sciences from a recognized University.

PhD in Natural Product Chemistry / Life Sciences / Pharmaceutical Sciences / Chemistry or related disciplines. 

Masters degree in Pharmacy / Pharmaceutical Sciences / Medicine / Chemistry / Biochemistry / Physics / Biotechnology / Biomedical engineering / Natural sciences.

First class post graduate degree (M.Pharm/M.S.(Pharm)/Ph.D. Second class post graduate degree (M.Pharm/M.S.(Pharm) with Ph.D.

BSc MLT/BSc. Nursing / BPH / B.Pharma / MSW. MBBS / BDS / BAMS / BHMS with MPH OR MSc / MSW with MBA in Health Care Management & Hospital administration.